Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the founding Director/Coordinator of Australian Centre for Vaccine Development (now named as QIMR Berghofer Centre for Immunotherapy and Vaccine Development). He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and is also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences and was awarded Order of Australia in 2017. He has extensive expertise in immunotherapy clinical trials, cancer immunology and vaccine development. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of cancer patients, transplant recipients and autoimmune diseases. Prof. Khanna has been appointed as a consultant to Atara Biotherapeutics (US), CSL Ltd, Cellestis Ltd and Oxford Immunotech (UK) for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by various national and International organizations for expert advice on developing clinical guidelines and scientific review.